An open label study on safety and pharmacokinetics of an intravenous administered single dose of Feramyl 200 mg in healthy blood donors compared to a single dose of Feramyl 1000 mg in IBD patients to evaluate dose dependency and kinetics after 1 hour infusion.

SerumWerk Bernburg AG0 个研究点目标入组 16 人开始时间: 2013年5月29日最近更新: 2014年3月24日

试验速览

暂无简介。

•Healthy volunteers:
•1. Blood donor, who have donated 400 ml blood within the last 2 weeks.
•2. The subject (male or female) is aged 18–45 years (inclusive).
•3. The subject's body mass index is between 20 and 28 kg/m2 (inclusive).
•4. The subject's systolic blood pressure is <135 mmHg AND his/her diastolic blood pressure is <95 mmHg.
•5. The subject has given negative results in serological tests for human immunodeficiency virus, hepatitis C virus and hepatitis B virus surface antigen.
•6. The subject has given his/her written informed consent to participate in the study by signing the Informed Consent form.
•Inflammatory bowel disease patients:
•1.Age between 18 and 70, both included.
•2.The subject's body mass index is between 20 and 28 kg/m2 (inclusive).
•3.Inflammatory bowel disease for at least 3 month.
•4.Anemic defined as Hgbg/l less than 12 (women), 13 (men), ferritin, ferritin < 800 ug/L andL and TSAT < 30 %.
•5.No other disease expected to reduce life expectancy.
•6. The subject has given his/her written informed consent to participate in the study by signing the Informed Consent form.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 12
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 4

•1. Known allergy to Feramyl or HES.
•2. The subject regularly takes multivitamin dietary supplement and/or iron supplement. (N.B. These will be prohibited during the study.)
•3. The subject (if female) is pregnant or lactating.
•4. The subject's laboratory values show any abnormality that the investigator considers to warrant exclusion of the subject from participation in the study.
•5. The subject has any history (or current presence) of addiction to alcohol or drugs.
•6. The subject has taken part in any other clinical trial within the previous three months
•7 Severe IBD, surgery within the last 8 weeks, non-iron deficient anemia, iron overload or hemosiderosis, liver cirrhosis or hepatitis, acute or chronic infections, rheumatic disease, pregnancy or breastfeeding, planned elective surgery during the study period.

发起方